Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study
Conclusion.East Asian patients with NUT carcinoma showed dismal survival outcomes like Western patients, and CUDC‐907 might be promising in NUT carcinoma treatment.Implications for Practice.NUT carcinoma (NC) is a disease caused by BRD‐NUT fusion leading to C‐MYC upregulation. NC is often misdiagnosed and very aggressive, requiring development of effective therapeutic strategy. This article presents the clinicopathological features of the largest series of NCs in East Asians and preclinical sensitivities to MYC‐targeting agents in NC cell lines. Patients with NC had grave outcomes and poor response to treatment. Among MYC‐targeting agents, including BET and HDAC inhibitors, CUDC‐907 (a dual PI3K/HDAC inhibitor) was most effective against NC cells, followed by panobinostat (an HDAC inhibitor) and AZD5153 (a bivalent BET inhibitor). CUDC‐907 might be promising in NC treatment.
Source: The Oncologist - Category: Cancer & Oncology Authors: Minsun Jung, Soyeon Kim, June-Koo Lee, Sun Och Yoon, Heae Surng Park, Soon Won Hong, Weon-Seo Park, Ji Eun Kim, Joon Kim, Bhumsuk Keam, Hyun Jik Kim, Hyoung Jin Kang, Dong-Wan Kim, Kyeong Cheon Jung, Young Tae Kim, Dae Seog Heo, Tae Min Kim, Yoon Kyung Je Tags: Head and Neck Cancers, Lung Cancer, Cancer Diagnostics and Molecular Pathology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HER2 | Lung Cancer | Pathology | Study